US CoQ10 Market Extends Bearish Trend as Mid-August Demand Cools

US CoQ10 99% CIF–Los Angeles prices moved lower in early August, with a modest decline recorded in the week ending August 16 as mid-summer buying patterns weighed on spot activity. Early August showed a broadly neutral market profile before mid-month softness emerged, driven largely by reduced procurement urgency among industrial buyers. Late-July freight easing and steady fermentation feedstock availability helped prevent a sharper drop, leaving overall market tone subdued rather than volatile. The weekly move reflects a continuation of a 12-week bearish stretch that has nudged CIF benchmarks lower through mid-August, per weekly assessment data.

Demand was bifurcated across end-markets. The dietary-supplement and nutraceutical segment remained the mainstay of demand, with cardiovascular-health, energy, anti-aging and functional-food applications sustaining structural offtake; our analysts note the US supplement industry remains the largest CoQ10 consumer globally, supporting baseline volumes. In contrast, pharmaceutical OEMs and contract manufacturers showed softer offtake, particularly among formulators on the US West Coast, which contributed to mid-month easing. Retail and wholesale channels were steady, with club-store promotions and online retail maintaining sell-through; stronger industrial sentiment in manufacturing—the manufacturing index stood at 55.6—offers an underlying procurement backdrop even as consumer inflation eased to 3.5%.

Supply dynamics were mixed but broadly supportive of a disciplined market. Fermentation feedstock — notably glucose — remained stable, allowing Asian fermenters to continue normal runs and sustain output. Logistics developments provided offsetting forces: ocean freight out of Shanghai softened in late July, easing some Trans-Pacific container pressure, while container rate volatility had previously added landed-cost uncertainty (reported container rates rose by about 26.6% on a recent comparison). Structural trade measures such as the 25% Section 301 tariff on Chinese-origin nutraceuticals continued to restrain arbitrage flows, keeping physical supply channels relatively disciplined. Looking ahead, planned production calendar shutdowns in China (Golden Week and Lunar New Year) and geopolitical shipping risks present upside tightness risks for forward availability.

Weekly pricing action showed a narrow trading range through July before a modest acceleration of downside in mid-August. Prices were largely flat in early July and through the first week of August as retail sell-through remained steady, then eased modestly in the second week of August and registered a mid-August dip per weekly assessment data. The week-on-week fall in early August underscored weakening order intake from nutraceutical manufacturers and OEMs, though the move remained limited in magnitude and did not reflect a market dislocation.

Outlook is mixed over the coming months, with our analysts seeing intermittent upside tied to Q4 US dietary-supplement procurement and holiday-season inventory building, while tariff effects and freight volatility will continue to shape landed costs. Price paths in the short term are likely to oscillate as buyers balance immediate inventories against forward procurement ahead of Chinese production holidays; this view is based on current market trends and remains subject to market conditions, including any escalation in shipping disruptions or unexpected shifts in industrial demand.